Joyvié Health Raises $1.04M to Redesign Continence Underwear

Jan de Vries · 2026-06-05

UK-based Joyvié Health has closed its pre-Seed funding round, raising a total of $1.04 million for its continence underwear. This product is designed from first principles to significantly reduce stool-to-skin contact, maintain skin integrity, and ease the burden on caregivers. The funding combines an Innovate UK grant with investments from HERmesa Angels, SyndicateRoom, Lavender Ventures, and individual angel investors. "Products designed for care should never cause harm. That's not a vision statement. It's the reason this company exists," says Zoe Robson, Founder & CEO of Joyvié Health. ### A Broader HealthTech Funding Wave Joyvié Health's pre-Seed round is part of a larger trend in 2026, with over $180 million in related HealthTech funding across the UK and Europe. Here's a snapshot of notable raises: - Semble raised $36.3 million to scale its healthcare management platform for outpatient providers. - Evaro secured $22 million to expand NHS-licensed embedded health services. - JAAQ closed $15.7 million to grow enterprise partnerships. - Calibre emerged from stealth with $2.9 million to tackle health "guesswork." - Nul raised $878,000 to launch its alcohol-dependence care platform. - Recare in Berlin raised up to $38.7 million to scale its AI platform for hospitals and care providers. - Patronus raised $11.5 million for a senior-friendly emergency smartwatch and family app. - Tucuvi raised $17.8 million to scale voice-AI nursing follow-up automation. - Ditto in Rotterdam raised $7.9 million to make medical information easier for patients to understand. - ShanX Medtech secured $25.1 million to advance antimicrobial-resistance diagnostics, with an initial women's health application in urinary tract infections. - MedVasc raised $2.3 million to progress its anesthesia catheter toward US approval.  ### The Personal Story Behind the Startup Joyvié Health was founded by Zoe Robson following the death of her father, Fred, in 2025. Fred was 77, fit, and sharp-minded when a late-stage pancreatic cancer diagnosis arrived without warning on Christmas Eve 2024. Eleven weeks later, he was gone. In those eleven weeks, Fred lost bowel control and had to wear a nappy. Feces trapped against skin breaks it down—moisture, pathogens, and pH imbalance do damage that never fully heals. His skin broke down. His dignity went with it, change by change. And Ruth, his wife and primary caregiver, carried a burden that was invisible to the world outside and impossibly hard to bear. "My parents didn't deserve that," says Zoe. "They were both at their most vulnerable—and the product meant to help them was making it worse. The skin breakdown, the shame, the loss of dignity, the weight on my mom. It wasn't from lack of care. It's a design failure." ### How Joyvié's Product Works The company is on a mission to end the silent humiliation of fecal incontinence (FI)—a condition affecting an estimated 656 million people globally. Yet the most common non-invasive solution remains unchanged for decades: nappies and pads. Where existing products trap feces against the skin, Joyvié contains stool in a disposable pouch immediately after excretion. This significantly reduces skin contact, preserves dignity, and cuts the time and burden of care. Early testing shows approximately 90% reduction in stool-to-skin contact and approximately 70% faster changes. "At Lavender Ventures, we are committed to backing founders addressing large, underserved markets with innovative solutions that can meaningfully improve people's lives," adds Gail Armstrong of Lavender Ventures. "We believe the market is ripe for innovation, and Joyvié's approach has the potential to deliver significant benefits not only for individuals, but also for carers, healthcare systems, and the environment." Fecal incontinence is often caused by age, illness, or injury—conditions that can strike anyone. Joyvié Health aims to offer a better, more dignified solution for millions.